# Interleukin-33 as an immune therapy for stroke

> **NIH VA I01** · VETERANS HEALTH ADMINISTRATION · 2020 · —

## Abstract

Stroke is one of the major medical concerns for United States military veterans. The classically neurocentric
view of the brain in stroke research may have hindered the development of effective therapies. White matter
(WM) injury, characterized by loss of myelin and myelin-producing oligodendrocytes (OLs), is a major cause of
functional disability after stroke but has not been widely appreciated until recently. Strategies that are able to
alleviate both gray matter and WM pathophysiology are needed to achieve full brain protection and long-term
neurological recovery. Accumulating evidence suggests that the different functional phenotypes of microglia/
macrophages contribute considerably to the regulation of inflammatory status of injured brain and ultimately
impact the brain integrity. Specifically, M2-like phenotype is essential for tissue preservation and brain repair
because M2 cells resolve local inflammation, clear cell debris, and provide protective factors.
 Interleukin-33 (IL-33) is a multifunctional cytokine that involves in a wide range of immune responses,
including potentiating M2-like responses in macrophages. Interestingly, both IL-33 and its receptor, which
consists of ST2 and IL-1 receptor accessory protein, are expressed in the CNS. The precise roles of IL-33/ST2
signaling in the ischemic brain, however, are not well-characterized and the underlying mechanisms of action
remain unknown. Our preliminary results show that ST2 knockout (KO) mice exhibited enlarged brain infarct,
deteriorated WM injury and worse sensorimotor deficits after transient middle cerebral artery occlusion (tMCAO).
In contrast, intranasal infusion of IL-33 1h after tMCAO attenuates brain infarct. Remarkably, ST2 KO mice
showed reduced expression of M2-like markers and increased expression of M1-like markers in the ischemic
brain. We have found in vitro that IL-33 potentiates M2 polarization, especially IL-10 production in primary
microglia. Furthermore, IL-33 treatment enhanced neuronal and OL survival against oxygen glucose deprivation
(OGD) in neuron-glia mixed culture, which can be abolished by IL-10 neutralizing antibody.
 This proposal will further explore the protective effect of IL-33/ST2 signaling after ischemic brain injury with
the hope of developing IL-33 into a novel, clinically feasible therapeutic strategy to ameliorate post-stroke brain
damage. We will test the overarching hypothesis that the activation of IL-33/ST2 signaling protects against
cerebral ischemia by enhancing microglia/macrophage polarization toward a protective M2 phenotype, which
in turn restricting neuronal and WM injury after stroke. The Specific Aims to be tested are: Aim 1: Test the
hypothesis that IL-33 post-treatment protects against focal cerebral ischemia in both young and aged mice. Aim
2: Test the hypothesis that IL-33/ST2 signaling ameliorates ischemic neuronal and OL damage via shifting
microglia toward a protective phenotype. Aim 3: Test the hypothesis that IL-10 is...

## Key facts

- **NIH application ID:** 9815352
- **Project number:** 5I01BX003651-02
- **Recipient organization:** VETERANS HEALTH ADMINISTRATION
- **Principal Investigator:** Xiaoming Hu
- **Activity code:** I01 (R01, R21, SBIR, etc.)
- **Funding institute:** VA
- **Fiscal year:** 2020
- **Award amount:** —
- **Award type:** 5
- **Project period:** 2018-10-01 → 2022-09-30

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/9815352

## Citation

> US National Institutes of Health, RePORTER application 9815352, Interleukin-33 as an immune therapy for stroke (5I01BX003651-02). Retrieved via AI Analytics 2026-05-22 from https://api.ai-analytics.org/grant/nih/9815352. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*